Hypertrophic cardiomyopathy: Can the noninvasive diagnostic testing identify high risk patients?  

作　　者：Li Zhang Obinna Mmagu Liwen Liu Dayuan Li Yuxin Fan Adrian Baranchuk Peter R Kowey 

机构地区：[1]Center for Clinical Cardiology,Lankenau Institute for Medical Research,Lankenau Medical Center,Jefferson Medical College,Philadelphia,PA 19096,United States [2]Department of Ultrasound,Xijing Hospital,Forth Military Medical University [3]HeartEast Heart Care,HealthEast Care System,St.Paul,MN 55102,United States [4]John Welsh Cardiovascular Diagnostic Laboratory,Department of Pediatrics-Cardiology,Baylor College of Medicine,Houston,TX 77030,United States [5]Arrhythmia Service,Kingston General Hospital,Queen’s University,K7L 2V7,Ontario,Canada

出　　处：《World Journal of Cardiology》2014年第8期764-770,共7页世界心脏病学杂志（英文版）（电子版）

基　　金：Supported by W.W.Smith Charitable Trust

摘　　要：Hypertrophic cardiomyopathy(HCM) is the most common cause of sudden cardiac death(SCD) in the young, particularly among athletes. Identifying high risk individuals is very important for SCD prevention. The purpose of this review is to stress that noninvasive diagnostic testing is important for risk assessment. Extreme left ventricular hypertrophy and documented ventricular tachycardia and fibrillation increase the risk of SCD. Fragmented QRS and T wave inversion in multiple leads are more common in high risk patients. Cardiac magnetic resonance imaging provides complete visualization of the left ventricular chamber, allowing precise localization of the distribution of hypertrophy and measurement of wall thickness and cardiac mass. Moreover, with late gadolinium enhancement, patchy myocardial fibrosis within the area of hypertrophy can be detected, which is also helpful in risk stratification. Genetic testing is encouraged in all cases, especially in those with a family history of HCM and SCD.Hypertrophic cardiomyopathy(HCM) is the most common cause of sudden cardiac death(SCD) in the young, particularly among athletes. Identifying high risk individuals is very important for SCD prevention. The purpose of this review is to stress that noninvasive diagnostic testing is important for risk assessment. Extreme left ventricular hypertrophy and documented ventricular tachycardia and fibrillation increase the risk of SCD. Fragmented QRS and T wave inversion in multiple leads are more common in high risk patients. Cardiac magnetic resonance imaging provides complete visualization of the left ventricular chamber, allowing precise localization of the distribution of hypertrophy and measurement of wall thickness and cardiac mass. Moreover, with late gadolinium enhancement, patchy myocardial fibrosis within the area of hypertrophy can be detected, which is also helpful in risk stratification. Genetic testing is encouraged in all cases, especially in those with a family history of HCM and SCD.

关 键 词：HYPERTROPHIC CARDIOMYOPATHY SUDDEN cardiac DEATH NONINVASIVE diagnostic testing 

分 类 号：R542.2[医药卫生—心血管疾病]